Vaxcell-Bio Therapeutics Statistics

Total Valuation

Vaxcell-Bio Therapeutics has a market cap or net worth of KRW 229.93 billion. The enterprise value is 183.09 billion.

Market Cap	229.93B
Enterprise Value	183.09B

Important Dates

Earnings Date	n/a
Ex-Dividend Date	n/a

Share Statistics

Vaxcell-Bio Therapeutics has 22.99 million shares outstanding. The number of shares has increased by 23.04% in one year.

Current Share Class	n/a
Shares Outstanding	22.99M
Shares Change (YoY)	+23.04%
Shares Change (QoQ)	n/a
Owned by Insiders (%)	19.61%
Owned by Institutions (%)	4.77%
Float	18.49M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	n/a
PB Ratio	2.93
P/TBV Ratio	2.98
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	-17.55
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-15.23

Financial Position

The company has a current ratio of 22.43, with a Debt / Equity ratio of 0.04.

Current Ratio	22.43
Quick Ratio	22.16
Debt / Equity	0.04
Debt / EBITDA	n/a
Debt / FCF	-0.23
Interest Coverage	-112.59

Financial Efficiency

Return on equity (ROE) is -21.52% and return on invested capital (ROIC) is -16.73%.

Return on Equity (ROE)	-21.52%
Return on Assets (ROA)	-16.22%
Return on Capital (ROIC)	-16.73%
Revenue Per Employee	n/a
Profits Per Employee	n/a
Employee Count	n/a
Asset Turnover	0.00
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -49.69% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	-49.69%
50-Day Moving Average	12,232.00
200-Day Moving Average	15,670.65
Relative Strength Index (RSI)	31.77
Average Volume (20 Days)	180,312

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Vaxcell-Bio Therapeutics had revenue of KRW 69.60 million and -10.43 billion in losses. Loss per share was -444.28.

Revenue	69.60M
Gross Profit	34.27M
Operating Income	-13.39B
Pretax Income	-10.43B
Net Income	-10.43B
EBITDA	-12.56B
EBIT	-13.39B
Loss Per Share	-444.28

Full Income Statement

Balance Sheet

The company has 49.60 billion in cash and 2.76 billion in debt, giving a net cash position of 46.85 billion or 2,037.40 per share.

Cash & Cash Equivalents	49.60B
Total Debt	2.76B
Net Cash	46.85B
Net Cash Per Share	2,037.40
Equity (Book Value)	78.27B
Book Value Per Share	3,408.50
Working Capital	49.75B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -10.55 billion and capital expenditures -1.46 billion, giving a free cash flow of -12.02 billion.

Operating Cash Flow	-10.55B
Capital Expenditures	-1.46B
Free Cash Flow	-12.02B
FCF Per Share	-522.73

Full Cash Flow Statement

Margins

Gross Margin	49.24%
Operating Margin	-19,244.85%
Pretax Margin	-14,989.18%
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

Vaxcell-Bio Therapeutics does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-23.04%
Shareholder Yield	-23.04%
Earnings Yield	-4.44%
FCF Yield	-5.23%

Stock Splits

The last stock split was on November 10, 2023. It was a forward split with a ratio of 1.2.

Last Split Date	Nov 10, 2023
Split Type	Forward
Split Ratio	1.2

Scores

Vaxcell-Bio Therapeutics has an Altman Z-Score of 54.93.

Altman Z-Score	54.93
Piotroski F-Score	n/a